Axinn Advised Thermo Fisher on $1.85B Acquisition of PeproTech, Inc.
January 5, 2022
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its approximately $1.85 billion acquisition of PeproTech, Inc., a leading developer and manufacturer of recombinant proteins. The deal closed on December 30, 2021. The Axinn antitrust team included partners John Harkrider and Mark Alexander, who were assisted by Craig Minerva, Tasneem Chowdhury, Megan Walden, and Kyle Sherwood.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
LegalNEXT 2025
Speaking Engagement
Antitrust
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust
Centerforce IP Strategy Summit: Palo Alto
Speaking Engagement
Intellectual Property
Consero Healthcare General Counsel Forum 2025
Speaking Engagement
Antitrust
CCWC 21st Annual Career Strategies Conference
Speaking Engagement
Pro Bono Partnership 28th Anniversary Gala
Sponsorship
Antitrust
Ronald McDonald House New York Together in Gold Annual Gala
Sponsorship
Antitrust
Fordham 52nd Annual Conference on International Antitrust Law and Policy
Speaking Engagement
Antitrust